Antiepileptic Drugs Market Size to Exceed USD 9.39 Bn by 2032

The Antiepileptic Drugs Market, estimated at USD 7.48 Bn in 2025, is expected to exhibit a CAGR of 3.3% and reach USD 9.39 Bn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

The key market players are focusing on adoption of inorganic growth strategies such as collabortions, and this is anticipated to drive the global Antiepileptic Drugs Market growth over the forecast period. For instance, in December 2025, UCB S.A, a global biopharmaceutical company, and Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, announced a strategic collaboration for the identification of small molecule therapies as possible treatments for KCNT1-related epilepsies based on Praxis' PRAX-020 program. Under the conditions of the collaboration, UCB S.A has the exclusive option to in-license global development and commercialization rights to any resulting KCNT1 small molecule development candidate.

Global Antiepileptic Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2025, as "coronavirus disease 2025" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others faced problems regarding the transportation from one place to another.

According to the Clinicaltrial.gov, in April 2025, there were more than 2,850 trials and approximately 900,000 patients enrolled at trial sites in the regions that were in partial or complete lockdown due to COVID-19 restrictions. While, the Research & Development (R&D) labs operated at below 50% of the normal capacity across the globe. Many companies with drug candidates for the treatment of epilepsy prioritized clinical trials based on their significant evidence of clinical activity and with held early-phase clinical trials, namely Phase I trials. Many research centers decided to freeze new trials and have stopped in-patient studies. Different pharmaceutical companies have also decided to delay the start of new clinical trials, suspended the enrollment in some trials, and have postponed the initiation of new sites in the case of trials continuing enrollment. Thus, the COVID-19 pandemic hampered the market development owing to cancellation of several ongoing clinical trials.

Global Antiepileptic Drugs Market: Key Developments

On February 7, 2025, Penn Medicine, a world-renowned academic medical center based in Philadelphia, U.S., and Children's Hospital of Philadelphia (CHOP), annouced that thet received donation of US$ 25 Mn from an undiscosed donor. This amount will be utilized to establish the Center for Epilepsy and Neurodevelopmental Disorders (ENDD), accelerating the collaborative research in genetic therapies for neurodevelopmental disorders. ENDD initially focused on developing medicines for disorders caused by mutations in the STXBP1 and SYNGAP1 genes, which are connected to abnormal brain function, intellectual disability, epilepsy, and motor and behavioral deficits.

In January 2025, Acadia Pharmaceuticals Inc., a biopharmaceutical company, and Stoke Therapeutics Inc., a biotechnology company, announced a collaboration to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental central nervous system (CNS) diseases. SYNGAP1 syndrome, Rett syndrome (MECP2), and an undisclosed neurodevelopmental target of common interest are all part of the collaboration. Mutations in the SYNGAP1 gene are also linked to the development of epileptic encephalopathies (DEEs).

In November 2025, Biogen Inc., a multinational biotechnology company, and Sage Therapeutics, Inc., a biopharmaceutical company, announced a global collaboration and license agreement to develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD), and other psychiatric disorders, as well as SAGE-324 for essential tremor and other neurological disorders. SAGE-324 is a next-generation positive allosteric modulator of γ-Aminobutyric acid type A (GABA_A) receptors under Phase 2 development for essential tremor, with potential applications in other neurological disorders such as epilepsy.

Browse 37 Market Data Tables and 31 Figures spread through 180 Pages and in-depth TOC on “Global Antiepileptic Drugs Market”- Forecast to 2032, Global Antiepileptic Drugs Market, By Generation (First Generation, Second Generation, and Third Generation), By Route Of Administration [Oral, Intravenous, and Others (Nasal, etc.)], By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-commerce), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/antiepileptic-drugs-market-1701

Key Takeaways of the Global antiepileptic drugs market:

Global antiepileptic drugs market is expected to exhibit a CAGR of 3.3% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global antiepileptic drugs market.
Among generation, the third generation segment is expected to hold the second highest share in the global antiepileptic drugs market during the forecast period, owing to rise in the number of regulatory approvals. For instance, in August, 2025, Eisai Co., Ltd., a pharmaceutical company, announced that its in-house discovered and developed anti-epileptic drug (AED) Fycompa has received two additional approvals in China as "a monotherapy for partial-onset seizures" and "an adjunctive treatment / a monotherapy for pediatric indication for partial onset seizures in patients with epilepsy 4 years of age and older" from the National Medical Products Administration.
Among region, North America is expected to be the dominant region in the global antiepileptic drugs market owing to increasing prevalence of epilepsey. According to a press release by the CDC in November 2025, around 3.4 million Americans suffer from epilepsy. One in every ten persons may suffer from a seizure during their lifetime. In the U.S., there are over 260 epilepsy centers. These centers' healthcare providers specialize in epilepsy management and offer expert care to both children and adults.
The major players operating in the global antiepileptic drugs market are Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy's Laboratories Ltd., Shanghai Zhimeng Biopharma, Inc., Alkem Labs, SK Biopharmaceuticals, Eisai Co., Ltd., IAMA Therapeutics, Angelini S.p.a, Sun Pharmaceutical Industries Ltd., UCB S.A, Marinus Pharmaceuticals, Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., and Bausch Health Companies Inc.